Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment

Abstract Background To compare the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment (PED) in age-related macular degeneration. Methods Eighty-three eyes of 83 patients diagnosed with type 1 macular neovascularization were included and retrospectively analysed using...

Full description

Bibliographic Details
Main Authors: Ryo Mukai, Hidetaka Matsumoto, Kazuki Nagai, Hideo Akiyama
Format: Article
Language:English
Published: BMC 2022-09-01
Series:BMC Ophthalmology
Subjects:
Online Access:https://doi.org/10.1186/s12886-022-02617-2
_version_ 1828108596017102848
author Ryo Mukai
Hidetaka Matsumoto
Kazuki Nagai
Hideo Akiyama
author_facet Ryo Mukai
Hidetaka Matsumoto
Kazuki Nagai
Hideo Akiyama
author_sort Ryo Mukai
collection DOAJ
description Abstract Background To compare the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment (PED) in age-related macular degeneration. Methods Eighty-three eyes of 83 patients diagnosed with type 1 macular neovascularization were included and retrospectively analysed using multimodal imaging. Forty-nine eyes were treated with intravitreal aflibercept injections (IVA group), and 34 eyes were treated with brolucizumab (IVBr group), with three consecutive injections administered as induction therapy. Before treatment and 1, 2, and 3 months after the first treatment, the maximum height (MH) and maximum diameter (MD) of the PED were measured using optical coherence tomography in each treatment group. Results In the IVA group, MH at baseline (228 ± 169 μm) diminished to 180 ± 150 (P = 0.2558), 165 ± 140 (P = 0.0962), and 150 ± 129 µm (P = 0.0284) at 1, 2, and 3 months after treatment, respectively; the reduction at 3 months was significant. In contrast, in the IVBr group, the MH was 307 ± 254 µm before treatment, and it decreased to 183 ± 156 µm (P = 0.0113), 139 ± 114 µm (P = 0.0003), and 125 ± 126 µm (P < 0.0001) at 1, 2, and 3 months after treatment, respectively, and the reduction at 1 month was significant. In both groups, the MD did not regress significantly. Conclusions The results suggested that the MH of PED after IVBr treatment regressed faster than that after IVA treatment.
first_indexed 2024-04-11T10:49:06Z
format Article
id doaj.art-aee9f5d4a10a4517ba23444134e4907f
institution Directory Open Access Journal
issn 1471-2415
language English
last_indexed 2024-04-11T10:49:06Z
publishDate 2022-09-01
publisher BMC
record_format Article
series BMC Ophthalmology
spelling doaj.art-aee9f5d4a10a4517ba23444134e4907f2022-12-22T04:28:58ZengBMCBMC Ophthalmology1471-24152022-09-012211610.1186/s12886-022-02617-2Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachmentRyo Mukai0Hidetaka Matsumoto1Kazuki Nagai2Hideo Akiyama3Department of Ophthalmology, Gunma University Graduate School of MedicineDepartment of Ophthalmology, Gunma University Graduate School of MedicineDepartment of Ophthalmology, Gunma University Graduate School of MedicineDepartment of Ophthalmology, Gunma University Graduate School of MedicineAbstract Background To compare the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment (PED) in age-related macular degeneration. Methods Eighty-three eyes of 83 patients diagnosed with type 1 macular neovascularization were included and retrospectively analysed using multimodal imaging. Forty-nine eyes were treated with intravitreal aflibercept injections (IVA group), and 34 eyes were treated with brolucizumab (IVBr group), with three consecutive injections administered as induction therapy. Before treatment and 1, 2, and 3 months after the first treatment, the maximum height (MH) and maximum diameter (MD) of the PED were measured using optical coherence tomography in each treatment group. Results In the IVA group, MH at baseline (228 ± 169 μm) diminished to 180 ± 150 (P = 0.2558), 165 ± 140 (P = 0.0962), and 150 ± 129 µm (P = 0.0284) at 1, 2, and 3 months after treatment, respectively; the reduction at 3 months was significant. In contrast, in the IVBr group, the MH was 307 ± 254 µm before treatment, and it decreased to 183 ± 156 µm (P = 0.0113), 139 ± 114 µm (P = 0.0003), and 125 ± 126 µm (P < 0.0001) at 1, 2, and 3 months after treatment, respectively, and the reduction at 1 month was significant. In both groups, the MD did not regress significantly. Conclusions The results suggested that the MH of PED after IVBr treatment regressed faster than that after IVA treatment.https://doi.org/10.1186/s12886-022-02617-2AfliberceptAge-related macular degenerationBrolucizumabPigment epithelial detachment
spellingShingle Ryo Mukai
Hidetaka Matsumoto
Kazuki Nagai
Hideo Akiyama
Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment
BMC Ophthalmology
Aflibercept
Age-related macular degeneration
Brolucizumab
Pigment epithelial detachment
title Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment
title_full Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment
title_fullStr Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment
title_full_unstemmed Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment
title_short Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment
title_sort comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment
topic Aflibercept
Age-related macular degeneration
Brolucizumab
Pigment epithelial detachment
url https://doi.org/10.1186/s12886-022-02617-2
work_keys_str_mv AT ryomukai comparisonoftheregressiveeffectsofafliberceptandbrolucizumabonpigmentepithelialdetachment
AT hidetakamatsumoto comparisonoftheregressiveeffectsofafliberceptandbrolucizumabonpigmentepithelialdetachment
AT kazukinagai comparisonoftheregressiveeffectsofafliberceptandbrolucizumabonpigmentepithelialdetachment
AT hideoakiyama comparisonoftheregressiveeffectsofafliberceptandbrolucizumabonpigmentepithelialdetachment